Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Milan
Clinical trial register · Italy

Clinical Trials in Milan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6791 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:19 UTC
6791
Studies in scope
all four open statuses
4079
Recruiting now
open to new participants
1019
Lead sponsors
across recruiting studies
Top sites
Milan 137 Naples 79 Roma 71 Florence 57 Padova 56
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
IRCCS San Raffaele160 AstraZeneca137 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Novartis Pharmaceuticals73 Clear sponsor filter
Site location
Milan137 Naples79 Roma71 Florence57 Padova56
All 111 locations
Target enrolment
to

Trials with a site in Milan

137 of 6791 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
AstraZeneca
Phase 3
2,800
Bari, Bologna, Cosenza, Cremona, Genoa, Milan, Modena, Naples
2026-09-01
Recruiting
AstraZeneca
Phase 3
1,072
Brescia, Cona, Florence, Milan, Roma
2026-08-31
Not yet open
AstraZeneca
Phase 3
750
Bologna, Milan, Rome, Rozzano, Torino
2026-08-25
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Ancona, Bergamo, Brescia, Milan, Pavia, Perugia, Riccione, Salerno
2026-08-24
Recruiting
AstraZeneca
Phase 3
2,500
Bologna, Milan, Palermo, Pisa, Roma, Rozzano, Sesto San Giovanni, Torino
2026-08-19
Recruiting
AstraZeneca
Phase 3
1,200
Bari, Bologna, Chieti, Milan, Modena, Naples, Roma
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Bologna, Catania, Chieti, Florence, Latina, Milan, Pisa, Ravenna
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Bologna, Milan, Rome, Rozzano, Torino
2026-06-26
Recruiting
AstraZeneca
Phase 3
150
Aviano, Bergamo, Genova, Milan, Naples
2026-06-15
Active, closed
AstraZeneca
Phase 2
326
Bologna, Florence, Milan, Padova, Pavia, Pisa, Torino, Torrette - Ancona
2026-06-11
Recruiting
AstraZeneca
Phase 2
80
Meldola, Milan, Padua, Ravenna, Rome, Torino
2026-06-04
Recruiting
AstraZeneca
Phase 1/2
152
Bergamo, Meldola, Milan, Roma
2026-06-03
Recruiting
AstraZeneca
Observational
200
Ancona, Bergamo, Foggia, Meldola, Milan, Modena, Naples, Padova
2026-04-16
Recruiting
AstraZeneca
Phase 3
245
Brescia, Catania, Ferrara, Florence, Milan, Padova, Pisa, Roma
2026-04-13
Recruiting
AstraZeneca
Phase 3
508
Bologna, Milan, Naples, Rozzano, Torino
2026-02-23
Recruiting
AstraZeneca
Phase 2
124
Milan, Padua, Roma, Rozzano
2026-02-10
Recruiting
AstraZeneca
Phase 3
2,130
Meldola, Milan, Padova, Rozzano, Tricase
2026-02-03
Recruiting
AstraZeneca
Phase 3
1,100
Brescia, Catania, Florence, Lecco, Milan, Naples, Parma, Pisa
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Castellana Grotte, Milan, Pisa, Rome, Rozzano
2025-12-04
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Milan, Orbassano, Pavia, Roma
2025-11-24
Recruiting
AstraZeneca
Phase 2
435
Milan, Palermo, Pavia, Perugia, Roma, Rozzano, Torrette
2025-11-06
Recruiting
AstraZeneca
Phase 3
400
Milan, Monza, Orbassano, Padova, Rozzano
2025-10-31
Recruiting
AstraZeneca
Phase 3
100
Aviano, Florence, Meldola, Milan, Naples, Roma
2025-10-30
Recruiting
AstraZeneca
Phase 1/2
283
Milan, Naples, Roma, Rozzano
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
91
Bologna, Milan
2025-09-24
Recruiting
AstraZeneca
Phase 2
278
Aviano, Catania, Meldola, Milan, Orbassano, Roma, Rozzano
2025-08-07
Recruiting
AstraZeneca
Phase 3
250
Bologna, Brescia, Florence, Milan, Torino
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Arezzo, Bari, Bergamo, Chieti, Genoa, Milan, Naples, Palermo
2025-08-06
Recruiting
AstraZeneca
Phase 3
800
Alessandria, Aviano, Bari, Bologna, Catania, Florence, Haifa, Milan
2025-08-01
Recruiting
AstraZeneca
Phase 2
100
Florence, Milan, Modena, Pisa, Rozzano, Udine, Vicenza
2025-07-17
Recruiting
AstraZeneca
Phase 2
987
Busto Arsizio, Cuneo, Ferrara, Milan, Monza, Naples, Pavia, Roma
2025-06-27
Recruiting
AstraZeneca
Phase 3
1,220
Bologna, Milan, Palermo, Perugia, Pisa, Roma, Rozzano
2025-05-06
Active, closed
AstraZeneca
Observational
2,000
Milan
2025-04-17
Recruiting
AstraZeneca
Phase 3
830
Candiolo, Lecco, Lucca, Meldola, Milan, Naples, Peschiera del Garda, Pisa
2025-04-10
Recruiting
AstraZeneca
Phase 3
400
Bari, Bergamo, Brescia, Cagliari, Catanzaro, Genoa, Milan, Modena
2025-03-28
Recruiting
AstraZeneca
Phase 3
600
Catania, Florence, Milan, Monza, Naples, Reggio Emilia, Roma, Rome
2025-03-27
Recruiting
AstraZeneca
Phase 3
990
Cona, Florence, Milan, Montebelluna, Naples, Pavia, Roma, Sassari
2025-03-18
Recruiting
AstraZeneca
Phase 3
11,300
Alessandria, Bari, Bergamo, Brescia, Chiavari, Cona, Foggia, Milan
2025-03-14
Recruiting
AstraZeneca
Phase 2
80
Bologna, Castelfranco Veneto, Florence, Milan, Naples, Pavia, Pisa, Roma
2025-03-12
Recruiting
AstraZeneca
Phase 3
840
Cagliari, Florence, Milan, Naples, Padova, Rozzano, Torino, Tricase
2025-03-01
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
DrugAcalabrutinib
AstraZeneca
Phase 4
60
Cagliari, Florence, Milan, Pavia, Perugia
2025-02-04
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Bologna, Milan
2025-01-30
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Alessandria, Bologna, Busto Arsizio, Milan, Roma
2024-11-27
Recruiting
AstraZeneca
Phase 3
744
Bari, Milan, Misterbianco, Monza, Naples, Orbassano, Padova, Parma
2024-10-04
Recruiting
AstraZeneca
Phase 1/2
174
Bologna, Milan
2024-09-18
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Milan, Roma, Rome
2024-08-28
Active, closed
AstraZeneca
Phase 2
194
Genoa, Meldola, Milan, Naples, Orbassano, Perugia, Rozzano, Udine
2024-08-27
Recruiting
AstraZeneca
Phase 3
620
Florence, Milan, Naples, Padova, Roma, Rozzano, Tricase
2024-08-12
Recruiting
AstraZeneca
Phase 3
788
Bergamo, Bologna, Milan, Modena, Naples, Padova, Reggio Emilia, Rome
2024-08-01
Active, closed
AstraZeneca
Phase 3
339
Brescia, Cona, Florence, Milan, Naples, Reggio Emilia, Roma, Rome
2024-06-29
Recruiting
AstraZeneca
Phase 3
240
Ancona, Bari, Catania, Milan, Padova, Palermo, Pavia, Pisa
2024-06-20
Recruiting
AstraZeneca
Phase 3
582
Milan, Monza, Orbassano, Padova, Parma
2024-04-29
Recruiting
AstraZeneca
Phase 3
675
Bergamo, Genoa, Milan, Monza, Padova, Pavia, Ravenna, Roma
2024-04-11
Active, closed
AstraZeneca
Phase 3
2,554
Bologna, Catanzaro, Chiavari, Desio, Milan, Naples, Parma, Rozzano
2024-03-29
Recruiting
AstraZeneca
Phase 3
100
Florence, Genova, Milan, Padova, Roma
2024-03-14
Active, closed
AstraZeneca
Phase 3
594
Florence, Milan, Naples, Padova, Pisa, Vicenza
2024-03-04
Active, closed
AstraZeneca
Phase 2
142
Bari, Bologna, Milan, Naples, Palermo, Pavia, Peschiera del Garda
2024-02-22
Recruiting
AstraZeneca
Phase 3
5,250
Ancona, Florence, Genoa, Mestre, Milan, Naples, Pavia, Perugia
2024-02-21
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
Alessandria, Bologna, Milan
2024-01-23
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Naples, Rome, Brescia, Milan, Rozzano, Turin, Monserrato, Pisa
2023-12-20
Recruiting
AstraZeneca
Phase 3
1,145
Aviano, Florence, Milan, Modena, Naples, Padova, Pavia, Rozzano
2023-12-14
Active, closed
AstraZeneca
Phase 3
760
Florence, Milan, Padova, Pisa, Rozzano, Tricase, Lecce
2023-12-04
Recruiting
AstraZeneca
Phase 3
625
Bergamo, Empoli, Milan, Modena, Naples, Padova, Reggio Emilia, Roma
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Bari, Genoa, Meldola, Milan, Naples, Padova, Rome, Rozzano
2023-11-21
Active, closed
AstraZeneca
Phase 3
1,902
Empoli, Lucca, Milan, Modena, Naples, Padova, Province of Macerata, Roma
2023-11-14
Active, closed
AstraZeneca
Phase 3
863
Alessandria, Bari, Bergamo, Milan, Monza, Orbassano, Padova, Parma
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Ancona, Brescia, Cona, Milan, Padova, Roma
2023-11-08
Active, closed
AstraZeneca
Phase 3
895
Bari, Bergamo, Milan, Padova, Parma, Pavia, Ravenna, Roma
2023-10-24
Active, closed
AstraZeneca
Phase 3
5,511
Bergamo, Bologna, Florence, Genoa, Meldola, Milan, Misterbianco, Monza
2023-10-05
Recruiting
AstraZeneca
Phase 3
800
Bari, Bologna, Catania, Florence, Lecco, Milan, Monza, Naples
2023-09-22
Recruiting
AstraZeneca
Observational
52,121
Lecce, Messina, Milan
2023-08-21
Active, closed
AstraZeneca
Phase 3
111
Milan, Naples, Padova, Pisa, Rozzano, Turin
2023-06-27
Active, closed
AstraZeneca
Phase 2
294
Florence, Milan, Naples, Rozzano
2023-04-24
Active, closed
AstraZeneca
Phase 3
94
Milan, Roma
2023-04-05
Recruiting
AstraZeneca
Phase 3
4,300
Bari, Catania, Catanzaro, Florence, Genova, Grosseto, Milan, Modena
2023-03-31
Active, closed
AstraZeneca
Phase 2
188
Avellino, Brescia, Lecce, Milan, Naples, Palermo, Peschiera del Garda, Reggio Emilia
2023-03-06
Active, closed
AstraZeneca
Observational
551
Naples, Cona, Udine, Rome, Brescia, Milan, Turin, Cagliari
2023-02-27
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Milan, Orbassano, Rozzano, Verona
2022-12-21
Active, closed
AstraZeneca
Phase 3
1,174
Bologna, Brescia, Florence, Genova, Livorno, Meldola, Messina, Milan
2022-11-28
Active, closed
AstraZeneca
Phase 3
368
Bologna, Milan, Naples, Padova, Pisa, Roma, Rozzano, Verona
2022-11-10
Active, closed
AstraZeneca
Phase 3
594
Aviano, Livorno, Meldola, Milan, Monza, Naples, Padova, Parma
2022-09-15
Recruiting
AstraZeneca
Phase 2
454
Florence, Genova, Milan, Naples, Rome
2022-09-06
Active, closed
AstraZeneca
Phase 2
194
Candiolo, Milan, Naples, Padova, Perugia, Roma, Siena
2022-08-11
Active, closed
AstraZeneca
Phase 3
341
Avellino, Aviano, Catania, Meldola, Milan, Modena, Monserrato, Naples
2022-08-03
Active, closed
AstraZeneca
Phase 1/2
174
Candiolo, Milan, Orbassano, Padova
2022-06-02
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Florence, Genova, Milan, Padova, Pavia, Roma, Torino, Trieste
2022-05-23
Active, closed
AstraZeneca
Phase 3
644
Borgo San Lorenzo, Catanzaro, Genova, Livorno, Milan, Modena, Naples, Province of Macerata
2022-05-16
By invitation
AstraZeneca
Phase 3
214
Arezzo, Bari, Catania, Meldola, Milan, Modena, Padova, Pisa
2022-04-19
Recruiting
AstraZeneca
Phase 2
630
Aviano, Brescia, Catanzaro, Florence, Genova, Meldola, Milan, Monza
2022-04-14
Active, closed
AstraZeneca
Phase 3
760
Arezzo, Florence, Milan, Roma, Rozzano, Tricase
2022-03-28
Active, closed
AstraZeneca
Phase 3
390
Bari, Catania, Florence, Genova, Milan, Naples, Padova, Parma
2022-02-21
Active, closed
AstraZeneca
Phase 1/2
36
Milan, Rome
2022-01-21
Active, closed
AstraZeneca
Phase 3
145
Milan, Naples, Roma
2021-11-19
Active, closed
AstraZeneca
Phase 3
148
Arezzo, Avellino, Bari, Bologna, Florence, Meldola, Milan, Naples
2021-10-28
Active, closed
AstraZeneca
Phase 3
454
Milan, Monza, Orbassano, Parma, Roma, Verona
2021-10-28
Active, closed
AstraZeneca
Phase 3
927
Bologna, Candiolo, Livorno, Milan, Naples, Negrar, Padova, Roma
2021-10-25
Active, closed
AstraZeneca
Phase 3
732
Bologna, Candiolo, Florence, Meldola, Milan, Naples, Padova, Prato
2021-10-18
Recruiting
AstraZeneca
Phase 1/2
460
Milan, Modena, Roma
2021-10-18
Active, closed
AstraZeneca
Phase 3
712
Bari, Florence, Meldola, Milan, Padova, Pozzuoli, Reggio Emilia, Roma
2021-08-05
Active, closed
AstraZeneca
Phase 3
315
Bergamo, Bologna, Florence, Meldola, Milan, Misterbianco, Naples, Padova
2021-06-30
Active, closed
AstraZeneca
Phase 3
506
Ancona, Bergamo, Catania, Milan, Naples, Padova, Prato
2021-06-22
Active, closed
AstraZeneca
Phase 3
1,157
Bergamo, Candiolo, Genova, Livorno, Milan, Naples, Padova, Rozzano
2021-04-26
Recruiting
AstraZeneca
Phase 1
304
Milan, Monza, Naples, Padova
2021-03-09
Active, closed
AstraZeneca
Phase 3
1,371
Bergamo, Florence, Milan, Modena, Naples, Novara, Padova, Parma
2021-01-28
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
Milan, Naples
2020-12-30
Active, closed
AstraZeneca
Phase 1/2
245
Bologna, Milan, Naples, Rome
2020-12-28
Active, closed
AstraZeneca
Phase 1/2
702
Milan, Modena, Naples, Padova, Roma
2020-11-12
Active, closed
AstraZeneca
Phase 3
370
Brescia, Candiolo, Florence, Milan, Modena, Naples, Padova
2020-10-02
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Milan, Naples, Rome
2020-08-18
Active, closed
AstraZeneca
Phase 3
185
Ancona, Bologna, Brescia, Candiolo, Catania, Lecce, Lecco, Milan
2020-08-04
Active, closed
AstraZeneca
Phase 3
866
Aviano, Bergamo, Candiolo, Cona, Genova, Livorno, Messina, Milan
2020-07-24
Active, closed
AstraZeneca
Phase 2
452
Milan, Naples, Padova, Roma, Verona
2020-06-03
Active, closed
AstraZeneca
Phase 2
240
Bologna, Catanzaro, Meldola, Messina, Milan, Monza, Naples, Roma
2020-04-22
Active, closed
AstraZeneca
Phase 3
818
Bergamo, Candiolo, Catanzaro, Livorno, Meldola, Milan, Modena, Naples
2020-04-16
Active, closed
AstraZeneca
Phase 3
140
Cuneo, Florence, Milan, Naples, Roma, Torino
2019-10-29
Active, closed
AstraZeneca
Phase 3
810
Faenza, Florence, Milan, Naples, Roma, Verona
2019-04-16
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Genova, Milan, Rome, Torino
2019-03-07
Active, closed
AstraZeneca
Phase 3
724
Florence, Genova, Milan, Orbassano, Padova, Pavia, Roma, Rozzano
2019-03-06
Active, closed
AstraZeneca
Phase 2
367
Avellino, Florence, Milan, Orbassano, Padova, Parma, Perugia, Peschiera del Garda
2019-01-09
Active, closed
AstraZeneca
Phase 3
1,407
Brescia, Lecce, Lecco, Milan, Mirano, Naples, Reggio Calabria, Reggio Emilia
2019-01-04
Active, closed
AstraZeneca
Phase 3
825
Ancona, Bari, Bergamo, Florence, Milan, Monza, Padova, Roma
2018-12-06
Active, closed
AstraZeneca
Phase 3
724
Arezzo, Brescia, Milan, Pisa
2018-11-30
Active, closed
AstraZeneca
Phase 3
1,063
Bari, Bologna, Florence, Milan, Naples, Orbassano, Pozzuoli, Verona
2018-11-16
Active, closed
AstraZeneca
Phase 3
895
Milan, Naples, Orbassano, Pavia
2018-10-31
Active, closed
AstraZeneca
Phase 3
730
Brescia, Milan, Orbassano, Parma, Roma, Rozzano, Terni
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Arezzo, Milan, Naples, Orbassano, Parma, Pavia, Roma, Terni
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,324
Benevento, Meldola, Milan, Naples, Perugia, Pisa, Roma, Rozzano
2017-10-11
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
DrugsSavolitinib·Sunitinib
AstraZeneca
Phase 3
60
Arezzo, Meldola, Milan, Modena, Orbassano, Pavia, Roma
2017-07-25
Active, closed
AstraZeneca
Phase 3
987
Bergamo, Meldola, Milan, Palermo, Roma, Terni
2017-03-27
Active, closed
AstraZeneca
Phase 3
1,126
Arezzo, Meldola, Milan, Naples, Orbassano, Pavia, Roma, San Giovanni Rotondo
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Bari, Bergamo, Bologna, Cremona, Florence, Lucca, Meldola, Milan
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,118
Genova, Meldola, Milan, San Giovanni Rotondo, Siena
2015-07-21
Active, closed
AstraZeneca
Phase 3
1,837
Bergamo, Bologna, Bolzano, Castellanza Varese, Lecce, Legnago, Milan, Modena
2014-04-22
Active, closed
AstraZeneca
Phase 3
510
Bari, Genova, Livorno, Milan, Naples, Orbassano, Parma, Perugia
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Milan, Modena, Naples, Padova, Roma
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Bari, Catania, Milan, Naples, Padova, Roma
2013-08-26
Active, closed
AstraZeneca
Phase 2
162
Genova, Milan, Monza, Torino
2010-02-04
Rows per page Showing 1–137 of 137
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-italy/city/milan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,791 studies in total at the last sync on 11 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 137 of those studies with a site in Milan that also match the filters currently applied.

How many clinical trials are recruiting in Milan?

60 of the 137 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 75 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Milan), 137 studies
PhaseStudiesRecruitingShare
Phase 3923767.2%
Phase 2231016.8%
Phase 1/21389.5%
Observational634.4%
Phase 1211.5%
Phase 4110.7%

Most active sponsors

Lead sponsors with the most studies (Milan)
Lead sponsorStudiesRecruiting
AstraZeneca13760
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.